Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 24, 2023

Trastuzumab Plus Ramucirumab and Paclitaxel for Previously Treated HER2-Positive Advanced Gastric or GEJ Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
J. Clin. Oncol 2023 Jun 26;[EPub Ahead of Print], CG Kim, M Jung, HS Kim, CK Lee, HC Jeung, DH Koo, WK Bae, DY Zang, BJ Kim, H Kim, UJ Yun, J Che, S Park, TS Kim, WS Kwon, J Park, SW Cho, CM Nam, HC Chung, SY Rha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading